Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096170 · ClinicalTrials.gov registry record · Phase 4
Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo
A Phase 4 study of Hernia, Paraesophageal, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04096170 is a Phase 4 study of Hernia, Paraesophageal that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04096170, a Phase 4 study of Hernia, Paraesophageal, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
We aim to study the impact of perioperative IV lidocaine on postoperative pain control in patients undergoing paraesophageal hernia repair. This is in the context of an established ERAS protocol. We wish to study the effect of IV Lidocaine on postoperative short and long-term outcomes, including patients' length of stay postoperative mortality, morbidity, and quality of life. We will compare this to our standard pain management.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IV lidocaine
Study Locations (1)
North Carolina
- Atrium Health - Carolinas Medical Center - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2026-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04096170
The ClinicalTrials.gov registry entry for NCT04096170 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hernia, Paraesophageal appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04096170 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04096170 about?
NCT04096170 is a clinical study titled "Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo". We aim to study the impact of perioperative IV lidocaine on postoperative pain control in patients undergoing paraesophageal hernia repair. This is in the context of an established ERAS protocol. We wish to study the effect of IV Lidocaine on postoperative short and long-term outcomes, including pat...
What is the current status of trial NCT04096170?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2018-06-21. Estimated completion is 2026-05.
What conditions does trial NCT04096170 study?
This clinical trial studies the following conditions: Hernia, Paraesophageal.
What interventions are being tested in trial NCT04096170?
The interventions under investigation include: Placebo (DRUG), IV lidocaine (DRUG).
Who is sponsoring clinical trial NCT04096170?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04096170 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.